A carregar...
miR‐181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression
Sorafenib, a multi‐kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long‐term efficacy. Therefore, novel targets and strategies are urgently needed to improve the ant...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5021022/ https://ncbi.nlm.nih.gov/pubmed/27384977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
A carregar...